FGEN - FibroGen, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
57.20
+2.60 (+4.76%)
As of 3:06PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close54.60
Open55.10
Bid57.30 x 100
Ask57.45 x 200
Day's Range54.75 - 58.10
52 Week Range22.75 - 63.00
Volume283,157
Avg. Volume584,983
Market Cap4.691B
Beta1.97
PE Ratio (TTM)N/A
EPS (TTM)-2.02
Earnings DateFeb 27, 2018 - Mar 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est69.00
Trade prices are not sourced from all markets
  • GlobeNewswire8 hours ago

    FibroGen to Report Fourth Quarter and Full Year 2017 Financial Results on Tuesday, February 27, 2018

    SAN FRANCISCO, Feb. 21, 2018-- FibroGen, Inc., a science-based biopharmaceutical company, today announced that it will report fourth quarter and full year 2017 financial results on Tuesday, February 27, ...

  • See what the IHS Markit Score report has to say about FibroGen Inc.
    Markit2 days ago

    See what the IHS Markit Score report has to say about FibroGen Inc.

    Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $83 million over the last one-month into ETFs that hold FGEN are among the lowest of the last year and appear to be slowing.

  • Why FibroGen Inc (NASDAQ:FGEN) Is A Financially Healthy Company
    Simply Wall St.4 days ago

    Why FibroGen Inc (NASDAQ:FGEN) Is A Financially Healthy Company

    Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as FibroGen Inc (NASDAQ:FGEN), with a market cap of US$4.63B, often get neglectedRead More...

  • See what the IHS Markit Score report has to say about FibroGen Inc.
    Markit19 days ago

    See what the IHS Markit Score report has to say about FibroGen Inc.

    Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold FGEN had net inflows of $454 million over the last one-month.

  • GlobeNewswire2 months ago

    Report: Exploring Fundamental Drivers Behind K2M Group, Altra Industrial Motion, FibroGen, Cardiovascular, Bluerock Residential Growth REIT, and National Presto Industries — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Jan. 04, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of K2M ...

  • Capital Cube2 months ago

    ETFs with exposure to FibroGen, Inc. : December 15, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to FibroGen, Inc. Here are 5 ETFs with the largest exposure to FGEN-US. Comparing the performance and risk of FibroGen, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of FGEN earnings conference call or presentation 8-Nov-17 10:00pm GMT

    Q3 2017 FibroGen Inc Earnings Call

  • See what the IHS Markit Score report has to say about FibroGen Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about FibroGen Inc.

    Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, ETFs holding FGEN are favorable with net inflows of $12.36 billion.

  • See what the IHS Markit Score report has to say about FibroGen Inc.
    Markit3 months ago

    See what the IHS Markit Score report has to say about FibroGen Inc.

    Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $3.00 billion over the last one-month into ETFs that hold FGEN are not among the highest of the last year and have been slowing.

  • Capital Cube3 months ago

    ETFs with exposure to FibroGen, Inc. : November 20, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to FibroGen, Inc. Here are 5 ETFs with the largest exposure to FGEN-US. Comparing the performance and risk of FibroGen, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • See what the IHS Markit Score report has to say about FibroGen Inc.
    Markit3 months ago

    See what the IHS Markit Score report has to say about FibroGen Inc.

    Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, ETFs holding FGEN are favorable, with net inflows of $3.46 billion.

  • ACCESSWIRE3 months ago

    Corporate News Blog - Protalix BioTherapeutics Gets Positive Opinion for Orphan Designation of PRX-102 for Treatment of Fabry Disease in EU

    Desk Line-up: FibroGen Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 15, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Protalix BioTherapeutics, ...

  • ACCESSWIRE3 months ago

    Featured Company News - FDA Approved Teligent's Betamethasone Dipropionate Ointment USP (Augmented), 0.05%

    Research Desk Line-up: FibroGen Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 14, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Teligent, ...

  • FibroGen, Inc. :FGEN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017
    Capital Cube3 months ago

    FibroGen, Inc. :FGEN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017

    Categories: Yahoo FinanceGet free summary analysis FibroGen, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of FibroGen, Inc. – Illumina, Inc., Acceleron Pharma Inc, Accelerate Diagnostics, Inc. and Harvard Bioscience, Inc. (ILMN-US, XLRN-US, AXDX-US and HBIO-US) that have also reported for this period. Highlights Summary ... Read more (Read more...)

  • See what the IHS Markit Score report has to say about FibroGen Inc.
    Markit3 months ago

    See what the IHS Markit Score report has to say about FibroGen Inc.

    Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $3.10 billion over the last one-month into ETFs that hold FGEN are not among the highest of the last year and have been slowing.

  • FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : November 10, 2017
    Capital Cube3 months ago

    FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : November 10, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for FibroGen, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)

  • Associated Press3 months ago

    FibroGen reports 3Q loss

    The San Francisco-based company said it had a loss of 50 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for ...

  • ACCESSWIRE3 months ago

    FibroGen, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 8, 2017 / FibroGen, Inc. (NASDAQ: FGEN ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 5:00 PM Eastern Time. ...

  • Is It Too Late To Buy FibroGen Inc (FGEN)?
    Simply Wall St.3 months ago

    Is It Too Late To Buy FibroGen Inc (FGEN)?

    FibroGen Inc (NASDAQ:FGEN), a biotechnology company based in United States, received a lot of attention from a substantial price increase on the NasdaqGS in the over the last few months.Read More...

  • Capital Cube4 months ago

    ETFs with exposure to FibroGen, Inc. : October 24, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to FibroGen, Inc. Here are 5 ETFs with the largest exposure to FGEN-US. Comparing the performance and risk of FibroGen, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)